GrittGene Therapeutics

Name

GrittGene Therapeutics

Legal name

GrittGene Therapeutics

Website

https://grittgene.com

Company type

Private

Founded year

2022

Operating status

Operating

Headcount range

1–10 employees

Ownership category

akta.pro rank

Product category

Biotechnology Therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in the Physical, Engineering, and Life Sciences (54171)

SIC

Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Gene Therapy for Rare/Monogenic Diseases (HLAAACAE)

akta.pro secondary industries

Neurology/CNS Gene Therapies (HLAAACAH), Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics) (HLAAAMAJ)

Keywords

• Myotonic dystrophy therapy
• Multi-omics drug discovery
• Cell therapy development
• Gene therapy research
• Rare disease therapeutics

Headquarters

HQ city

Glendale

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations

Revenue model

1. Therapeutic Development and Licensing: Pre-revenue biotech company developing treatments for genetically complex diseases. Revenue model will likely involve licensing therapeutic candidates to pharmaceutical partners or commercializing therapies upon regulatory approval.

Go-to-market motion1 record

Marketing channels1 record

Core offering

GrittGene Therapeutics develops a diversified, multi-modality therapeutic pipeline (Cell Therapy, Gene Therapy, Biologics, Diagnostics) for genetically complex diseases, anchored by an AI-powered multi-omics platform that integrates transcriptomics, proteomics, and epigenomics to identify therapeutic targets. The company is conducting a DM2 natural history multi-omics study and developing therapeutic programs for Myotonic Dystrophy Type 2 (DM2), with the platform designed to extend into broader neuromuscular and rare disease indications.

Product overview

GrittGene Therapeutics offers a diversified, multi-modality therapeutic platform consisting of four core products: Cell Therapy (regenerative muscle repair strategies), Gene Therapy (targeted genetic interventions), Biologics (precision disease pathway modulation), and Diagnostics (disease detection and monitoring). These products are built on an AI-driven multi-omics platform that integrates transcriptomics, proteomics, and epigenomics data. The company focuses initially on Myotonic Dystrophy Type 2 (DM2) as its clinical and scientific entry point, with the platform designed to be scalable across complex genetic disorders and neuromuscular diseases.

Differentiator

Problem solved

Functional benefit

Products and services

• Cell Therapy

Segments2 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature2 records

Partnerships

One partnership is on record.

• International Experts, Clinicians, and ResearcherscoreStrategic or Co-development PartnerCollaborates with international experts, clinicians, and researchers in neuromuscular and rare diseases to advance understanding of DM2 and develop therapeutic approaches. Partnership focuses on deep scientific and clinical understanding.

Scale indicators2 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Regenxbio: Established AAV gene therapy platform company with multiple clinical programs in rare diseases. Comparable as a broad gene therapy infrastructure and rare-disease peer relevant to GrittGene's gene therapy track.
• uniQure: Clinical-stage AAV gene therapy company focused on rare and serious diseases. Comparable as an established rare-disease gene therapy peer relevant to GrittGene's gene therapy modality.
• Sarepta Therapeutics: Established commercial-stage leader in gene therapy for neuromuscular diseases (DMD, LGMD). Comparable as a broad incumbent operating in the same neuromuscular/rare muscle-disease therapeutic space that GrittGene's cell and gene therapy programs target.

Direct peers

• Expansion Therapeutics: Focused on developing oral small molecules and other therapies for repeat-expansion diseases including DM1 and DM2. Direct peer in addressing myotonic dystrophy through multiple therapeutic approaches.
• Dyne Therapeutics: Clinical-stage biotech developing oligonucleotide and antibody-based therapeutics for DM1 and DM2, making it the most directly comparable myotonic dystrophy peer to GrittGene's DM2-focused pipeline.
• AMO Pharma: Clinical-stage rare disease company developing therapeutics for DM1 and congenital myotonic dystrophy. Comparable as a small rare-disease biotech focused on the myotonic dystrophy patient population.
• Avidity Biosciences: Develops antibody-RNA conjugate (ARC) therapeutics for DM1 and other rare muscle diseases. Comparable as a modality-platform biotech tackling repeat-expansion muscle disorders with multiple parallel programs.
• Design Therapeutics: Clinical-stage biotech developing small-molecule 'designer DNA' therapies for DM1 and other repeat-expansion disorders. Directly comparable as a DM-focused therapeutic developer with a platform-based approach to genetically defined diseases.

Emerging players

• Juvena Therapeutics: AI-driven protein therapeutics platform focused on muscle regeneration and age-related muscle disease. Directly comparable on the muscle-regeneration cell/biology angle and on the AI-driven discovery approach.
• Recursion Pharmaceuticals: AI-driven drug discovery company combining high-throughput biology with machine learning to identify therapeutic candidates. Comparable as a platform peer applying AI/ML to drug discovery across multiple disease areas.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/grittgene-therapeutics

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about GrittGene Therapeutics